Leukemia & Lymphoma最新文献_第2页

The maturing picture of CPX-351 in acute myeloid leukemia: long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in England. CPX-351治疗急性髓性白血病的成熟图景：英国CPX-351治疗急性髓性白血病的长期实际经验。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-28 DOI: 10.1080/10428194.2026.2656725

Alex Legg, Alexandrina Lambova, Eleanor Ralphs, Karabo Keapoletswe, Gry Wester, Tomas Skacel

引用次数: 0

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma. 在三线或晚期复发或难治性滤泡性淋巴瘤中，异卡布他烯与外部对照组的比较结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-28 DOI: 10.1080/10428194.2026.2650672

Loretta Jo Nastoupil, Alejandro Martín García-Sancho, Koji Izutsu, Guillaume Cartron, Alan Pierre Zausner Skarbnik, Juan Luis Reguera Ortega, Hideki Goto, Peter Borchmann, Thalia Farazi, Merav Bar, Maria Del Rosario Olivera, Jinender Kumar, Marc De Benedetti, Fangyi Gu, Dara Stein, Jenny Han, Maria Lia Palomba

{"title":"Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.","authors":"Loretta Jo Nastoupil, Alejandro Martín García-Sancho, Koji Izutsu, Guillaume Cartron, Alan Pierre Zausner Skarbnik, Juan Luis Reguera Ortega, Hideki Goto, Peter Borchmann, Thalia Farazi, Merav Bar, Maria Del Rosario Olivera, Jinender Kumar, Marc De Benedetti, Fangyi Gu, Dara Stein, Jenny Han, Maria Lia Palomba","doi":"10.1080/10428194.2026.2650672","DOIUrl":"https://doi.org/10.1080/10428194.2026.2650672","url":null,"abstract":"In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL). Here, we compared efficacy and safety of liso-cel from TRANSCEND FL to standard-of-care (SOC [excluding T-cell-engaging therapies]) by constructing an external control arm (ECA) of patients from historical clinical trials and real-world practice. Using inverse probability of treatment weighting (IPTW), ECA cohort was balanced to match TRANSCEND FL. After IPTW, liso-cel-treated patients had significantly higher ORR (relative risk: 1.4; 95% confidence interval [CI]: 1.3-1.6) and CR rate (2.4; 2.1-2.7) than SOC. Adjusted hazard ratios (95% CI) for duration of response (0.26; 0.15-0.46), time to next treatment (0.24; 0.13-0.44), progression-free survival (0.28; 0.17-0.48), and overall survival (0.40; 0.19-0.84) significantly favored liso-cel, demonstrating meaningful efficacy improvement with liso-cel over SOC, solidifying liso-cel as a treatment option for patients with 3 L + FL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia. 急性淋巴细胞白血病儿童和青少年的天冬酰胺酶活性水平和毒性。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-25 DOI: 10.1080/10428194.2026.2656726

Marie-Claude Pelland-Marcotte, Chantal Éthier, Alexis Manirakiza, Heloise Perrault, Elsa Trombino, Caroline Laverdière, Tiago Nava, Yves Théorêt, Jean-Marie Leclerc, James A Whitlock, Émilie Martineau, Marie-Pier Desjardins, Mahukpe Narcisse U Singbo, Thai Hoa Tran

{"title":"Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia.","authors":"Marie-Claude Pelland-Marcotte, Chantal Éthier, Alexis Manirakiza, Heloise Perrault, Elsa Trombino, Caroline Laverdière, Tiago Nava, Yves Théorêt, Jean-Marie Leclerc, James A Whitlock, Émilie Martineau, Marie-Pier Desjardins, Mahukpe Narcisse U Singbo, Thai Hoa Tran","doi":"10.1080/10428194.2026.2656726","DOIUrl":"https://doi.org/10.1080/10428194.2026.2656726","url":null,"abstract":"Asparaginase (ASP) is a critical treatment component of acute lymphoblastic leukemia (ALL), yet associated with potentially severe complications. We assessed whether serum asparaginase activity (SAA) is associated with development of venous thrombosis, acute pancreatitis, bleeding and/or hypersensitivity events. We included 84 patients (median age 6.4 years, 66% male) with newly diagnosed ALL/lymphoblastic lymphoma who received ≥1 dose of ASP and with ≥1 available SAA level(s). Median peak and trough SAA levels were 2.36 IU/mL and 0.77 IU/mL. High peak SAA levels were associated with a trend toward increased venous thrombosis risk (HR: 1.51, p = 0.058). No association between SAA peak and/or trough levels and acute pancreatitis nor hypersensitivity was observed. SAA do not appear to predict the risk of ASP-related toxicities. Our data do not support individualized dosing to prevent toxicities such as thrombosis or pancreatitis. Larger prospective studies are required to help identify children at high risk of ASP-related toxicities.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma. 弥漫性大b细胞淋巴瘤一线扎鲁替尼治疗的真实多中心研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-24 DOI: 10.1080/10428194.2026.2654977

Lina Hu, Bo Lu, Xiaolei Wei, Ying Wang, Mian Xie, Jun Li, Chun Feng, Guoqiang Li, Xiao Qiu, Jiahe Zhang, Xutao Guo, Zhiren Zhong, Xiaoqing Li, Qian Zhang, Jihao Zhou

{"title":"A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.","authors":"Lina Hu, Bo Lu, Xiaolei Wei, Ying Wang, Mian Xie, Jun Li, Chun Feng, Guoqiang Li, Xiao Qiu, Jiahe Zhang, Xutao Guo, Zhiren Zhong, Xiaoqing Li, Qian Zhang, Jihao Zhou","doi":"10.1080/10428194.2026.2654977","DOIUrl":"https://doi.org/10.1080/10428194.2026.2654977","url":null,"abstract":"We conducted a retrospective, multi-center, real-world study to evaluate efficacy and safety of zanubrutinib combination therapy as first-line treatment for diffuse large B-cell lymphoma (DLBCL) between August 2020 and August 2025. Patients received RCHOP as standard therapy, while those with central nervous system (CNS) involvement were treated with R plus high-dose methotrexate (R + HD-MTX). Seventy patients were enrolled: 53 (75.7%) received RCHOP and17 (24.3%) received R + HD-MTX. The complete response rate (CRR) was 88.6% and the overall response rate (ORR) was 92.9%. The estimated 2-year progression-free survival (PFS) rate was 79.3% and the estimated 2-year overall survival (OS) rate was 98.1%. The estimated 2-year PFS was significantly higher in MCD (MYD88mut/CD79Bmut) subtype than non-MCD subtype (100% vs. 70.1%, p = 0.011). No treatment-related deaths were reported. Zanubrutinib combination therapy showed favorable efficacy in first-line DLBCL, particularly in BTK inhibitor-sensitive patients, with a manageable safety profile and low rates of severe adverse events.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca²⁺ signaling pathway. MBP1通过下调非典型Wnt/Ca2+信号通路抑制AML增殖。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-23 DOI: 10.1080/10428194.2026.2661083

Beibei Gao, Wenli Yan, Jingjing Xue, Shanshan Zhang, Furong Wang, Zhijie Kang, Jinhong Ren, Jinsong Yan, Haina Wang

{"title":"MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca2+ signaling pathway.","authors":"Beibei Gao, Wenli Yan, Jingjing Xue, Shanshan Zhang, Furong Wang, Zhijie Kang, Jinhong Ren, Jinsong Yan, Haina Wang","doi":"10.1080/10428194.2026.2661083","DOIUrl":"https://doi.org/10.1080/10428194.2026.2661083","url":null,"abstract":"Acute myeloid leukemia (AML) remains therapeutically challenging, highlighting an urgent need for novel therapeutic targets. Our prior work showed ENO1 promotes AML, but the role of its short variant MBP1 was unknown. Here, we demonstrated significant downregulation of MBP1 alongside ENO1 upregulation in primary AML patient samples compared to healthy donors, establishing an imbalanced ENO1/MBP1 ratio. Functionally, restoring MBP1 expression in AML cell lines (KG1, OCI-AML3) inhibited cell proliferation, suppressed colony formation, induced cell apoptosis, and triggered G1-phase cell cycle arrest in vitro. Mechanistically, RNA-seq and pathway analysis revealed that MBP1 overexpression suppresses the non-canonical Wnt/Ca2+ signaling pathway by downregulating its key components Wnt11 and NFATc1. Crucially, in vivo studies using NSG mouse xenografts confirmed that MBP1 overexpression significantly attenuated AML progression, reducing tumor burden in spleen and bone marrow. These results demonstrate that MBP1 deficiency promotes AML via Wnt11/NFATc1 activation, revealing a promising therapeutic target.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular deconstruction of anaplastic large cell Lymphoma (ALCL). 间变性大细胞淋巴瘤（ALCL）的分子解构。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-22 DOI: 10.1080/10428194.2026.2661081

Steven P Zielske, Rodrigo Fernandez-Valdivia

引用次数: 0

Clinicopathological factors associated with the prognosis and relapse of primary cutaneous marginal zone lymphoma: a retrospective cohort study. 与原发性皮肤边缘区淋巴瘤预后和复发相关的临床病理因素：一项回顾性队列研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-21 DOI: 10.1080/10428194.2026.2656942

Ik Jun Moon, Jihun Choi, Joon Min Jung, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee

{"title":"Clinicopathological factors associated with the prognosis and relapse of primary cutaneous marginal zone lymphoma: a retrospective cohort study.","authors":"Ik Jun Moon, Jihun Choi, Joon Min Jung, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee","doi":"10.1080/10428194.2026.2656942","DOIUrl":"https://doi.org/10.1080/10428194.2026.2656942","url":null,"abstract":"Primary cutaneous marginal zone lymphoma (PCMZL) is a rare extranodal B-cell lymphoma with limited data available in Asian populations. We reviewed 56 primary and 10 secondary CMZL cases (1995-2024) diagnosed at Asan Medical Center (Seoul, Korea). The PCMZL cohort showed an equal sex distribution, and lesions most frequently involved the head and neck (53.6%). Autoimmune diseases were present in 10.7% of PCMZL patients. Five-year overall survival for PCMZL was 96.4%, although only 39.3% maintained complete remission. Single lesions were significantly associated with initial clinical remission (p = 0.032). Widespread disease (other than T1a or T2a), older age (≥ 65 years), and underlying autoimmune disease were significantly associated with shorter relapse-free survival (RFS). Multivariate analysis identified autoimmune disease as an independent predictor of shorter RFS (p = 0.018). These findings suggest distinct clinical features of PCMZL in Korean patients, including sex ratio and lesion distribution, that differ from Western studies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defined genetic abnormalities shape the clonal hierarchy in acute myeloid leukemia as founding events. 定义遗传异常塑造克隆层次在急性髓系白血病的创始事件。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-21 DOI: 10.1080/10428194.2026.2659222

Anetta Marcinek, Sandra Huber, Stephan Hutter, Manja Meggendorfer, Torsten Haferlach, Constance Baer

引用次数: 0

From JAK to CALR: redefining therapeutic targets in myeloproliferative neoplasms. 从JAK到CALR：重新定义骨髓增生性肿瘤的治疗靶点。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-19 DOI: 10.1080/10428194.2026.2658135

Anushri Soni, Amit Verma, Swati Goel

引用次数: 0

Pregnancy in women with myelodysplastic syndromes: a scoping review of maternal, obstetric, and neonatal outcomes. 妊娠与骨髓增生异常综合征的妇女：一个范围审查产妇，产科和新生儿的结局。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2026-04-16 DOI: 10.1080/10428194.2026.2653811

Shehab F Mohamed, Fadel Alqatati, Marrita Rabadi, Maria Benkhadra, Angham Ibrahim Tartour, Ayman Dalol, Mymuna Hekmat, Ruba Adel Aweer, Abdulrahman F Al-Mashdali, Mohammed Abdulgayoom, Naseema Gangat

{"title":"Pregnancy in women with myelodysplastic syndromes: a scoping review of maternal, obstetric, and neonatal outcomes.","authors":"Shehab F Mohamed, Fadel Alqatati, Marrita Rabadi, Maria Benkhadra, Angham Ibrahim Tartour, Ayman Dalol, Mymuna Hekmat, Ruba Adel Aweer, Abdulrahman F Al-Mashdali, Mohammed Abdulgayoom, Naseema Gangat","doi":"10.1080/10428194.2026.2653811","DOIUrl":"https://doi.org/10.1080/10428194.2026.2653811","url":null,"abstract":"Myelodysplastic syndromes (MDS) are rare in women of reproductive age, and evidence regarding pregnancy outcomes remains limited. A systematic literature search identified 21 publications reporting MDS recognized before or during pregnancy, encompassing 69 pregnancies. The data were descriptively analyzed and stratified by timing of MDS diagnosis. Of the 69 pregnancies, 52% involved women diagnosed with MDS before conception, while 48% were diagnosed during pregnancy. Leukemic transformation occurred exclusively among cases diagnosed during pregnancy. The majority of pregnancies resulted in live births, with rates exceeding 93% in both groups, and neonatal complications being uncommon. MDS diagnosed during pregnancy appears to confer higher maternal risk, underscoring the need for early recognition and multidisciplinary management. This scoping review suggests that pregnancy can be successfully carried to term in selected women with MDS, particularly when disease stability is established prior to conception.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0